Publisher
Centre for Evaluation in Education and Science (CEON/CEES)
Reference40 articles.
1. Health Statistical Yearbook of Republic of Serbia 2016. Institute of Public Health of Serbia “Dr Milan Jovanovic Batut”, Belgrade, 2016, available at: http://www.batut.org.rs/download/publikacije/pub201620171103.pdf (last accessed on May 10th 2018);
2. Sher T, Dy GK, Adjei AA. Small Cell Lung Cancer. Mayo Clin Proc. 2008;83(3):355-67.;
3. Besse B, Adjei A, Baas P, et al. 2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease. Ann Oncol. 2014;25(8):1475-1484.;
4. Antoniu S, Ulmeanu R. Nivolumab for advanced non-small cell lung cancer: an immunologicallymediated tumor checkout. Ann Transl Med 2016;4(10):201.;
5. Valecha GK, Vennepureddy A, Ibrahim U, Safa F, Samra B, Atallah JP. Anti-PD-1/PD-L1 antibodies in non-small cell lung cancer: the era of immunotherapy. Expert Rev Anti-cancer Ther. 2017;17(1):47-59.;